NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that as part of a planned succession, its Board of Directors has appointed Warren Stone, current President and Chief Operating Officer (COO), as Chief Executive Officer (CEO) and a member of the Board, effective January 4, 2027. Tony Zook, the Company’s current CEO and a member of the Board, will assume the role of Executive Chair at that time and will continue to work in close alignment with Mr. Stone and the Board.

In conjunction with Mr. Zook being named Executive Chair, long-time Chair of the Board, Lynn Tetrault, will continue to serve as an independent director until the 2027 Annual Meeting of Stockholders, at which point she does not intend to stand for reelection. The Board appointed Michael Kelly, a current independent Board member since 2020, as the new Lead Independent Director effective January 4, 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.